Sign In
Buy BCYC
$4.20
-0.1000 (-2.33%)
At Close: Jun 03, 2026
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
05:00pm, Thursday, 21'st May 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
07:00am, Thursday, 30'th Apr 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
10:31am, Tuesday, 21'st Apr 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
07:00am, Monday, 20'th Apr 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
10:55am, Thursday, 16'th Apr 2026
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares
04:59am, Tuesday, 07'th Apr 2026
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an av
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts
02:35am, Sunday, 05'th Apr 2026
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rating of "Hold" from the eleven brokerages that are currently covering the stock, Marketbeat.com repor
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
10:35am, Tuesday, 24'th Mar 2026
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Monday, 23'rd Mar 2026
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
07:00am, Wednesday, 18'th Mar 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
07:00am, Tuesday, 17'th Mar 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
01:28am, Saturday, 14'th Feb 2026
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat report
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
07:00am, Tuesday, 03'rd Feb 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
07:00am, Monday, 12'th Jan 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerages
02:02am, Friday, 26'th Dec 2025
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are covering the firm, MarketBeat Ratings re
